Johnson Investment Counsel Inc. Has $257,000 Holdings in Biogen Inc. (NASDAQ:BIIB)

Johnson Investment Counsel Inc. lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 18.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,679 shares of the biotechnology company’s stock after selling 386 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Biogen were worth $257,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Larson Financial Group LLC boosted its position in Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Biogen in the fourth quarter worth $32,000. Ashton Thomas Securities LLC bought a new stake in shares of Biogen during the 3rd quarter worth $33,000. SRS Capital Advisors Inc. acquired a new position in Biogen in the 4th quarter valued at $33,000. Finally, Golden State Wealth Management LLC bought a new position in Biogen in the 4th quarter worth $41,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of recent analyst reports. Stifel Nicolaus cut shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 price target for the company. in a report on Monday, December 16th. Citigroup cut their price objective on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Wolfe Research assumed coverage on Biogen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. StockNews.com lowered Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Finally, William Blair restated an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $213.33.

Biogen Stock Down 0.1 %

Shares of NASDAQ BIIB opened at $139.98 on Friday. Biogen Inc. has a 52-week low of $128.51 and a 52-week high of $238.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The business has a fifty day moving average of $143.35 and a two-hundred day moving average of $165.02. The stock has a market cap of $20.49 billion, a PE ratio of 12.51, a PEG ratio of 1.51 and a beta of 0.01.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.